Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Aaron Dane, MSc

Director
Danestat Consulting Limited
Macclesfield, England, United Kingdom

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

731 - CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
Thursday, October 20, 2022
2:00 PM – 2:15 PM US ET
754 - Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32)
Thursday, October 20, 2022
2:30 PM – 2:45 PM US ET
870 - Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
Friday, October 21, 2022
11:00 AM – 11:15 AM US ET